natgillin/translations-raw huggingface dataset:
Although this may be caused by their anti-cancer treatment, it can also be caused by Savene, because it is a cytotoxic (a medicine that destroys cells that are multiplying) that can affect the bone marrow. 
To je lahko posledica zdravljenja proti raku, vendar pa tudi zdravila Savene, saj je tudi to zdravilo citotoksično (uničuje celice, ki se množijo) in lahko prizadene kostni mozeg.
Savene should not be used in people who may be hypersensitive (allergic) to dexrazoxane or any of the other ingredients. 
Zdravila Savene ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) deksrazoksan ali katero koli drugo sestavino zdravila.
The infusion should last between one and two hours, and be given at a site other than where the extravasation happened. 
Infuzija mora trajati eno do dve uri, mesto injiciranja pa ne sme biti isto kot je mesto, kjer je prišlo do ekstravazacije.
The CHMP concluded that Savene had shown its ability to treat anthracycline extravasation, allowing patients to continue their anticancer treatment. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da je zdravilo Savene izkazalo učinkovitost pri zdravljenju antraciklinske ekstravazacije, kar bolnikom omogoča nadaljevanje zdravljenja proti raku.
What is Savene? 
Kaj je zdravilo Savene?
Savene is a powder and diluent that are made up into a solution for infusion (drip into a vein). 
Zdravilo Savene sestavljata prašek in vehikel, namenjena za pripravo raztopine za infundiranje (dajanje v veno).
Savene is used to treat extravasation of anthracyclines (a group of anticancer medicines). 
Zdravilo Savene se uporablja za zdravljenje antraciklinske ekstravazacije(ki jo povzroča skupina zdravil proti raku).
How is Savene used? 
Kako se zdravilo Savene uporablja?
How has Savene been studied? 
Kako je bilo zdravilo Savene raziskano?
What is Savene used for? 
Za kaj se zdravilo Savene uporablja?
The active substance in Savene, dexrazoxane, is an antidote to anthracyclines. 
Zdravilna učinkovina zdravila Savene, deksrazoksan, je antidot (protisredstvo) antraciklinov.
The full EPAR for Savene can be found here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Savene je na voljo tukaj.
How does Savene work? 
Kako zdravilo Savene deluje?
Enzepi is available as capsules (5,000; 10,000; 25,000 and 40,000 units). 
Na voljo je v obliki kapsul (5 000, 10 000, 25 000 in 40 000 enot).
Treatment is started at a low dose, which the doctor may then increase slowly until an appropriate dose is reached. 
Zdravljenje se začne z nizkim odmerkom, ki ga zdravnik nato lahko počasi povečuje do ustreznega odmerka.
The full EPAR for Enzepi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Enzepi je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Other information about Enzepi 
Druge informacije o zdravilu Enzepi
In one main study involving 96 patients, treatment with Enzepi led to the absorption of 84% of the fats consumed by patient over 72 hours compared with 85% absorption with the already authorised medicine. 
V glavni študiji, v katero je bilo vključenih 96 bolnikov, je zdravljenje z zdravilom Enzepi privedlo do absorpcije 84 % maščob, ki jih je bolnik zaužil v 72 urah, pri že odobrenem zdravilu pa do absorpcije 85 % maščob.
This is a summary of the European public assessment report (EPAR) for Enzepi. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Enzepi.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Enzepi's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Enzepi večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Enzepi should be taken during meals or snacks with a drink of water or juice. 
Zdravilo Enzepi je treba vzeti z obrokom ali prigrizkom, skupaj s kozarcem vode ali soka.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Enzepi have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila Enzepi, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The appropriate dose depends on the symptoms of the disease, amount of fat in the stool, fat content of the diet and the patient's weight. 
Ustrezni odmerek je odvisen od simptomov bolezni, količine maščobe v blatu, deleža maščob v prehrani in bolnikove telesne mase.
What measures are being taken to ensure the safe and effective use of Enzepi? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila
The most common side effects with Enzepi (which may affect more than 1 in 100 people) are effects on the gut (abdominal pain, bloating, diarrhoea, vomiting, constipation and nausea) and headache. 
Najpogostejši neželeni učinki zdravila Enzepi (ki lahko prizadenejo več kot 1 osebo od 100) so učinki na črevesje (bolečine v trebuhu, napihnjenost, driska, bruhanje, zaprtost in slabost) ter glavobol.
For patients who cannot swallow capsules, the capsules may be opened and the content mixed with a small amount of acidic food such as fruit puree which should be swallowed immediately without chewing. 
Pri bolnikih, ki kapsul ne morejo pogoltniti, se kapsule lahko odprejo in njihova vsebina zmeša z majhno količino kisle hrane, kot je sadna kaša.
What benefits of Enzepi have been shown in studies? 
Kakšne koristi je zdravilo Enzepi izkazalo v študijah?
Enzepi was shown to be as effective as the already well-known marketed medicine. 
Zdravilo Enzepi se je izkazalo za enako učinkovito kot dobro poznano zdravilo, ki je že na trgu.
What is Enzepi and what is it used for? 
Kaj je zdravilo Enzepi in za kaj se uporablja?
It is not intended to provide practical advice on how to use Enzepi. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Enzepi will therefore help the body absorb nutrients better, especially fats. 
Zdravilo Enzepi bo telesu pomagalo hranila, zlasti maščobe, bolje absorbirati.
For more information about treatment with Enzepi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Enzepi preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The most important serious side effects observed with all pancreatic enzyme medicines are anaphylactic (allergic) reactions and fibrosing colonopathy (scarring and thickening of the bowel wall). 
Najpomembnejši resni neželeni učinki, opaženi pri vseh zdravilih z encimi trebušne slinavke, so anafilaktične (alergijske) reakcije in fibrozirajoča kolonopatija (brazgotinjenje in zadebelitev črevesne stene).
In clinical trials most side effects were mild to moderate in severity. 
V kliničnih preskušanjih so bili neželeni učinki večinoma blagi do zmerni.
A lack of these enzymes leads to poor growth, weight loss, abdominal pain and diarrhoea. 
Pomanjkanje teh encimov povzroča upočasnjeno rast, izgubo telesne mase, bolečino v trebuhu in drisko.
What are the risks associated with Enzepi? 
Kakšna tveganja so povezana z zdravilom Enzepi?
The CHMP considered that the use of pancreas powder to treat pancreatic insufficiency has been well established in medical practice for more than 20 years. 
Odbor CHMP je ugotovil, da je uporaba uprašenega pankreasa za zdravljenje pomanjkljivega delovanja trebušne slinavke v medicini dobro uveljavljena že več kot 20 let.
Why is Enzepi approved? 
Zakaj je bilo zdravilo Enzepi odobreno?
For practical information about using Enzepi, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Enzepi naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
EPAR summary for the public 
Povzetek EPAR za javnost uprašeni pankreas
It contains enzymes that help with the digestion of fats, carbohydrates and proteins. 
Vsebuje encime, ki pomagajo pri prebavi maščob, ogljikovih hidratov in beljakovin.
Pancreas enzymes are needed to digest fats, carbohydrates and proteins. 
Encimi trebušne slinavke so potrebni za prebavo maščob, ogljikovih hidratov in beljakovin.
In terms of safety, Enzepi's side effects are comparable to other marketed products. 
Z vidika varnosti so neželeni učinki zdravila Enzepi primerljivi z neželenimi učinki drugih zdravil na trgu.
Enzepi is a medicine used to treat adults and children whose pancreas does not produce enough enzymes (a condition known as pancreatic insufficiency) due to cystic fibrosis or other conditions such as pancreatic cancer. 
Zdravilo Enzepi se uporablja za zdravljenje odraslih in otrok, pri katerih trebušna slinavka zaradi cistične fibroze ali drugih bolezni, npr. raka trebušne slinavke, ne proizvaja dovolj encimov (bolezen, znana kot pomanjkljivo delovanje trebušne slinavke).
For the full list of restrictions and all side effects reported with Enzepi, see the package leaflet. 
Za celoten seznam omejitev in neželenih učinkov, o katerih so poročali pri uporabi zdravila Enzepi, glejte navodilo za uporabo.
Enzepi has been shown to be as effective as an already authorised medicine containing pancreas powder and used in pancreatic insufficiency. 
Zdravilo Enzepi se je izkazalo za enako učinkovito kot že odobreno zdravilo, ki vsebuje uprašeni pankreas in se uporablja pri pomanjkljivem delovanju trebušne slinavke.
Pancreas powder is a well-known substance that has been authorised in the treatment of pancreatic insufficiency for many years. 
Uprašeni pankreas je dobro poznana snov, ki je za zdravljenje pomanjkljivega delovanja trebušne slinavke odobrena že vrsto let.
The active substance of Enzepi, pancreas powder, is intended to replace missing enzymes in patients whose pancreas does not produce sufficient amounts of them. 
Zdravilna učinkovina v zdravilu Enzepi, uprašeni pankreas, je namenjena nadomeščanju encimov pri bolnikih, pri katerih jih trebušna slinavka ne proizvaja v zadostni količini.
Enzepi can only be obtained with a prescription. 
Predpisovanje in izdaja zdravila Enzepi je le na recept.
How does Enzepi work? 
Kako zdravilo Enzepi deluje?
The active substance in Enzepi is pancreas powder which is obtained from pig pancreas. 
Zdravilna učinkovina v zdravilu Enzepi je uprašeni pankreas, pridobljen iz trebušne slinavke prašičev.
How is Enzepi used? 
Kako se zdravilo Enzepi uporablja?
Intravenous use vial (glass) 
25mg/ml koncentrat za raztopino za infundiranje intravenska uporaba viala (steklo)
Blepharitis; keratitis. 
blefaritis; keratitis.
a) Grade 1: 
a) 1. stopnja:
Such patients should be closely monitored. 
Take bolnike je treba skrbno spremljati.
They can occur despite the use of premedication. 
Pojavijo se lahko kljub uporabi premedikacije.
The recommended infusion period is 120 minutes. 
Priporočena dolžina infuzije je 120 minut.
The pharmacokinetic results were comparable to those in adults. 
Rezultati farmakokinetike so bili primerljivi s tistimi pri odraslih.
Overall, no clinically relevant difference between genders was observed. 
Na splošno niso opažali nobene klinično pomembne razlike med spoloma.
In this study EGFR expression was not an inclusion criterion. 
V tej študiji ekspresija EGFR ni bila vključitveni kriterij.
Your doctor will then discuss with you the risks and benefits of using Erbitux in these situations. 
Zdravnik se bo potem z vami pogovoril o tveganjih in koristih uporabe zdravila Erbitux v teh situacijah.
RAS is one of the most frequently activated family of oncogenes in human cancers. 
RAS je ena od najpogosteje aktiviranih družin onkogenov pri človeških rakih.
Availability of resuscitation equipment must be ensured. 
Vedno mora biti na voljo oprema za oživljanje.
Such reactions may be allergic in nature. 
Te reakcije so lahko alergijske.
Your doctor will discuss appropriate measures with you. 
Vaš zdravnik se bo z vami pogovoril o ustreznih ukrepih.
Tell your doctor if you are pregnant or if you are not using reliable contraception (speak to your doctor if you are not sure). 
Povejte zdravniku, če ste noseči ali ne uporabljate zanesljive kontracepcije (če niste prepričani, se pogovorite z zdravnikom).
• excessive growth of hair 
• prekomerna rast dlak
On the basis of this data and since no independent review of imaging data was conducted, results in relation to mutation status are considered non-interpretable. 
Na podlagi teh podatkov, in ker neodvisnega pregleda podatkov slikanja niso opravili, velja, da rezultatov statusa mutacije ni mogoče razlagati.
Before the first dose, you will receive an antiallergic medicine in order to reduce the risk of an allergic reaction. 
Pred prvim odmerkom boste prejeli še zdravilo proti alergijam, da bi zmanjšali tveganje za pojav alergijske reakcije.
1082 MA Amsterdam The Netherlands 
1082 MA Amsterdam Nizozemska
Variable/ statistic 
Spremenljivka/statistika
From a microbiological point of view, the product shall be used immediately after opening. 
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj po odprtju.
Increase in liver enzyme levels (ASAT, ALAT, AP). 
povečanje ravni jetrnih encimov (ASAT, ALAT, AP).
Thus, a benefit-risk ratio for this combination has not yet been established. 
Zato še ni bilo postavljeno razmerje med koristjo in tveganjem za to kombinacijo.
Your doctor will discuss with you whether you may need any preventive measures or early treatment. 
Vaš zdravnik se bo z vami pogovoril, ali morebiti potrebujete preventivne ukrepe ali zgodnje zdravljenje.
• severe breathing difficulties which develop rapidly 
• hude težave z dihanjem, ki se pojavijo hitro
However, since it does not contain any antimicrobial preservative or bacteriostatic agent, it is intended for immediate use. 
Ker pa ne vsebuje antimikrobnih konzervansov ali bakteriostatikov, je namenjeno za takojšnjo uporabo.
Skin reactions*. 
kožne reakcije*.
For details, see section 5.1. 
Za podrobnosti glejte poglavje 5.1
Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany 
Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Nemčija
Your doctor will discuss with you whether you need to consult a specialist. 
Vaš zdravnik se bo z vami pogovoril, ali se morate posvetovati s specialistom.
Data for the XELOX regimen and the third experimental arm are not presented. 
Podatki za režim XELOX in tretjo eksperimentalno skupino niso predstavljeni.
continue slow infusion under close supervision b) Grade 2: 
nadaljujte s počasnim infundiranjem pod skrbnim nadzorom b) 2. stopnja:
As a result of this binding, the cancer cell can no longer receive the messages it needs for growth, progression and metastasis. 
Zaradi te vezave rakava celica ne more več sprejemati sporočil, ki jih potrebuje za rast, napredovanje procesa in metastaziranje.
For the subsequent weekly doses, the recommended infusion period is 60 minutes. 
Za kasnejše tedenske odmerke je priporočena dolžina infuzije 60 minut.
A close monitoring of patients, particularly during the first administration, is required. 
Bolnike je treba skrbno spremljati, zlasti med prvim dajanjem.
The efficacy data generated in this study are summarised in the table below: 
Podatki o učinkovitosti, ki so bili zbrani v tej študiji, so povzeti v spodnji preglednici:
Approximately 15% of the skin reactions are severe, including single cases of skin necrosis. 
Približno 15% kožnih reakcij je hudih, vključno s posameznimi primeri nekroze kože.
It is recommended to warn patients of the possibility of such a late onset and instruct them to contact their physician if symptoms or signs of an infusion-related reaction occur. 
Priporočljivo je, da bolnike opozorite na možnost takšne pozne reakcije in jim naročite, naj pokličejo svojega zdravnika, če se pojavijo simptomi ali znaki reakcije, povezane z infundiranjem.
If keratitis is diagnosed, the benefits and risks of continuing treatment should be carefully considered. 
Če se diagnosticira keratitis, je treba skrbno pretehtati koristi in tveganja nadaljevanja zdravljenja.
EGFR activates proteins called RAS. RAS proteins play an important role in the EGFR pathway -a complex signalling cascade which is involved in the development and progression of cancer. 
EGFR aktivira proteine, imenovane RAS. Proteini RAS imajo pomembno vlogo pri poti EGFR - zapleteni kaskadi signaliziranja, ki sodeluje v razvoju in napredovanju raka.
Erbitux is used to treat two different types of cancer: 
Zdravilo Erbitux se uporablja za zdravljenje dveh različnih vrst raka:
This premedication is recommended prior to all subsequent infusions. 
Ta premedikacija je priporočljiva tudi pred vsemi naslednjimi infuzijami.
The efficacy data on the OxMdG regimen generated in this study are summarised in the table below: 
Podatki o učinkovitosti režima OxMdG, ki so bili zbrani v tej študiji, so povzeti v spodnji preglednici:
Your doctor will calculate the correct dose of Erbitux for you because it depends on your body surface area. 
Zdravnik bo izračunal pravilen odmerek zdravila Erbitux za vas, saj je ta odvisen od telesne površine.
Monoclonal antibodies are proteins that specifically recognise and bind to other unique proteins called antigens. 
Monoklonska protitelesa so beljakovine, ki specifično prepoznavajo in se vežejo na druge točno določene beljakovine, ki jih imenujemo antigeni.
For storage conditions after opening, see section 6.3. 
Za pogoje shranjevanja po prvem odprtju zdravila glejte poglavje 6.3.
Effects on male and female fertility have not been evaluated within formal animal studies (see section 5.3). 
Učinkov na plodnost pri moških in ženskah niso ugotavljali v formalnih študijah na živalih (glejte poglavje 5.3).
Cases of interstitial lung disease (ILD), including fatal cases, have been reported, with the majority of patients from the Japanese population. 
Poročali so o primerih intersticijske pljučne bolezni (IPB), med katerimi so bili tudi smrtni primeri, pri čemer je bila večina bolnikov pripadnikov japonske populacije.
• chest pain (a symptom of side effects on your heart) If such symptoms occur, speak to a doctor immediately. 
• bolečine v prsnem košu (znak neželenih učinkov na srce) Če se pojavijo taki simptomi, se nemudoma pogovorite z zdravnikom.
If you have heart problems, your doctor will discuss with you whether you can receive Erbitux in combination with other anticancer medicines, especially if you are 65 years of age or older. 
Če imate težave s srcem, se bo vaš zdravnik z vami pogovoril, ali lahko prejemate zdravilo Erbitux v kombinaciji z drugimi zdravili proti raku, zlasti, če ste stari 65 let ali več.
Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. 
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, tudi če ste ga dobili brez recepta.
• a certain type of cancer of the head and neck (squamous cell cancer). 
• Določenega tipa raka glave in vratu (raka skvamoznih celic).
If you notice other extensive skin alterations, please inform your doctor as soon as possible because the Erbitux dose or the time between infusions may need to be changed. 
Če opazite drugo obsežno kožno spremembo, morate čim prej obvestiti zdravnika, saj bo morda treba spremeniti odmerek zdravila Erbitux ali čas med infundiranji.
Your doctor will decide whether treatment has to be stopped if skin reactions reappear after several dose reductions. 
Vaš zdravnik se bo odločil, ali bo treba z zdravljenjem prenehati, če se kožna reakcija ponovno pojavi po večkratnih zmanjšanjih odmerka.
In these patients cetuximab should be administered only after a careful assessment of benefit/risk, including alternative treatments, and only under close supervision of well trained personnel with resuscitation equipment ready. 
Pri teh bolnikih je treba dati cetuksimab samo po skrbni oceni koristi in tveganj, vključno z alternativnim zdravljenjem, in le pod skrbnim nadzorom dobro usposobljenega osebja in pripravljeno opremo za oživljanje.
If such symptoms occur, please inform your doctor as soon as possible. 
Če se pojavijo tovrstni učinki, morate čim prej obvestiti zdravnika.
It is strongly recommended that Erbitux be given during pregnancy or to any woman not employing adequate contraception only if the potential benefit for the mother justifies a potential risk to the foetus. 
Močno priporočamo, da zdravilo Erbitux uporabljate med nosečnostjo ali pri katerikoli ženski brez ustrezne kontracepcije samo, če njegova pričakovana korist za mater upraviči morebitno tveganje za plod.
• inflammation of the lining of the intestine, mouth, and nose (in some cases severe), which may lead to nose bleeding in some patients 
• vnetje sluznice črevesa, ust in nosu (v nekaterih primerih resno), ki lahko pri nekaterih bolnikih povzroči krvavitev iz nosu
If the severe skin reaction occurred for the first time, treatment may be resumed without any change in dose level. 
Če se je huda kožna reakcija pojavila prvič, lahko z zdravljenjem nadaljujete brez kakršnekoli spremembe velikosti odmerka.
Electrolyte repletion is recommended, as appropriate. 
Po potrebi se priporoča nadomeščanje elektrolitov.
Once opened, Erbitux is intended for immediate use. 
Po odprtju je zdravilo Erbitux namenjeno za takojšnjo uporabo.
Treatment may only be resumed if the reaction has resolved to grade 2. 
Z zdravljenjem smete nadaljevati le, če se je reakcija izboljšala do 2. stopnje.
They usually disappear over time after the end of Erbitux therapy. 
Ponavadi sčasoma izginejo po koncu zdravljenja z zdravilom Erbitux.
KRAS mutational status was available for 2072 patients. 
Mutacijski status KRAS so lahko določili pri 2072 bolnikih.
In clinical studies with doses up to 700 mg/m 2 given every 2 weeks the safety profile was consistent with that described in section 4.8. 
V kliničnih študijah z odmerki do 700 mg/m², ki so se dajali vsaka dva tedna, je bil varnostni profil skladen s profilom, opisanim v poglavju 4.8.
Talk to your doctor before using Erbitux, if any of the following information is not clear. 
Pred začetkom uporabe zdravila Erbitux se posvetujte z zdravnikom, če vam katera od naslednjih informacij ni jasna.
Treatment with Erbitux must then be stopped. 
Zdravljenje z zdravilom Erbitux je treba takrat ustaviti.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 29/06/2004 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 29/06/2004 Datum zadnjega podaljšanja: 29/06/2009
The majority of skin reactions develop within the first three weeks of therapy. 
Večina kožnih reakcij se pojavi v prvih treh tednih zdravljenja.
The infusion rate must not exceed 10 mg/min. 
Hitrost infuzije ne sme preseči 10 mg/min.
Animal data revealed no evidence of teratogenicity. 
Podatki pri živalih niso pokazali dokazov o teratogenosti.
Do not use Erbitux if you have ever had a severe hypersensitivity (allergic) reaction to cetuximab. 
Ne uporabljajte zdravila Erbitux, če ste imeli kdaj hudo preobčutljivostno (alergijsko) reakcijo na cetuksimab.
If during the first infusion, an infusion-related reaction occurs within the first 15 minutes, the infusion should be stopped. 
Če se med prvim infundiranjem v prvih 15 minutah pojavi reakcija, povezana z infundiranjem, je treba infundiranje ustaviti.
If patients experience treatment-related symptoms affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides. 
Če ima bolnik simptome, povezane z zdravljenjem, ki vplivajo na njegovo zbranost in reakcijsko sposobnost, priporočamo, naj ne vozi ali upravlja strojev, dokler vpliv zdravila ne preneha.
Hypomagnesaemia (see section 4.4). 
hipomagneziemija (glejte poglavje 4.4).